6-Amino-3-chloro-2-(piperazine-1-sulfonyl)-phenol | 364363-79-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-Amino-3-chloro-2-(piperazine-1-sulfonyl)-phenol
• 英文别名: 6-amino-3-chloro-2-piperazin-1-ylsulfonylphenol
• CAS: 364363-79-1
• 化学式: C₁₀H₁₄ClN₃O₃S
• 分子量: 291.758
• InChiKey: PVGXCONGHXTBPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-Amino-3-chloro-2-(piperazine-1-sulfonyl)-phenol 在 三氟乙酸 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 N-[4-chloro-2-hydroxy-3-(1-piperazinylsulfonyl)phenyl]-N'-(2,3-dichlorophenyl)urea
  参考文献：
  名称：

  Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders

  摘要：

  Structure-activity relationship exploration of the historical biarylurea series led to the identification of novel CNS penetrant CXCR2 antagonists with nanomolar potency, favorable PK profile, and good developability potentials. More importantly, the key compound 22 showed efficacy in a cuprizone-induced demyelination model with twice daily oral administration, thereby supporting CXCR2 to be a potential therapeutic target for the treatment of demyelinating diseases such as multiple sclerosis.

  DOI：

  10.1021/acsmedchemlett.5b00489
• 作为产物：
  描述：

  tert-butyl 4-((2-(tert-butyl)-6-chlorobenzo[d]oxazol-7-yl)sulfonyl)piperazine-1-carboxylate 在 硫酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 5.0h， 生成 6-Amino-3-chloro-2-(piperazine-1-sulfonyl)-phenol
  参考文献：
  名称：

  Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders

  摘要：

  Structure-activity relationship exploration of the historical biarylurea series led to the identification of novel CNS penetrant CXCR2 antagonists with nanomolar potency, favorable PK profile, and good developability potentials. More importantly, the key compound 22 showed efficacy in a cuprizone-induced demyelination model with twice daily oral administration, thereby supporting CXCR2 to be a potential therapeutic target for the treatment of demyelinating diseases such as multiple sclerosis.

  DOI：

  10.1021/acsmedchemlett.5b00489

文献信息

• Il-8 receptor antagonists
  申请人：——

  公开号：US20040048897A1

  公开（公告）日：2004-03-11

  This invention relates to the novel use of sulfonamide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  这项发明涉及磺胺基苯并二酰胺在治疗由趋化因子白细胞介素-8（IL-8）介导的疾病状态中的新用途。
• Il-8 receptor anatagonists
  申请人：——

  公开号：US20030216375A1

  公开（公告）日：2003-11-20

  This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  该发明涉及式(I)的新化合物及其组合物，用于治疗由趋化因子白细胞介素-8（IL-8）介导的疾病状态。
• IL-8 receptor antagonists
  申请人：McCleland Brent

  公开号：US20060084641A1

  公开（公告）日：2006-04-20

  This invention relates to the novel use of sulfonamide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

  本发明涉及磺酰胺方酰胺在治疗由趋化因子白细胞介素-8（IL-8）介导的疾病状态中的新用途。
• Method of Treatment
  申请人：Busch-Petersen Jakob

  公开号：US20090281110A1

  公开（公告）日：2009-11-12

  This invention relates to the use of sulfonamide substituted diphenyl urea compounds to treat endometriosis.

  本发明涉及使用磺酰胺取代的二苯基脲化合物治疗子宫内膜异位症。
• METHOD OF TREATMENT
  申请人：Busch-Petersen Jakob

  公开号：US20100256157A1

  公开（公告）日：2010-10-07

  This invention relates to the use of a sulfonamide substituted diphenyl urea compound to treat cystic fibrosis, or the symptoms associated with cystic fibrosis.

  本发明涉及使用磺酰胺取代的二苯基脲化合物治疗囊性纤维化或与囊性纤维化相关的症状。